Results 11 to 20 of about 9,620 (164)

Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy

Scientific Reports, 2021
Canakinumab is a fully human monoclonal antibody that specifically neutralizes human interleukin (IL)-1β and has been approved by the US Food and Drug Administration for treating different types of autoinflammatory disorders such as cryopyrin-associated ...
Wen-Wei Lin, Yun-Chi Lu, Bo-Cheng Huang, Chih-Hung Chuang, Yi-An Cheng, I.-Ju Chen, Hui-Ju Liu, Kai-Wen Ho, Tzu-Yi Liao, En-Shuo Liu, Ting-Yi Wu, Long-Sen Chang, Shih-Ting Hong, Tian-Lu Cheng   +13 more
doaj   +1 more source

Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases

The Turkish Journal of Pediatrics, 2020
Background and Objectives. The aim of this observational retrospective cohort study was to demonstrate indications and response rates of the patients with pediatric rheumatic diseases that used canakinumab. Method. The files of the patients
Mustafa Çakan, Şerife Gül Karadağ, Nuray Aktay Ayaz   +2 more
doaj   +1 more source

Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

EClinicalMedicine, 2022
Summary: Background: Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population.
Matthias Hepprich, Jonathan M. Mudry, Claudia Gregoriano, Francois R. Jornayvaz, Sebastian Carballo, Anne Wojtusciszyn, Pierre-Alexandre Bart, Jean-Daniel Chiche, Stefan Fischli, Thomas Baumgartner, Claudia Cavelti-Weder, Dominique L. Braun, Huldrych F. Günthard, Felix Beuschlein, Anna Conen, Emily West, Egon Isenring, Stefan Zechmann, Gabriela Bucklar, Yoann Aubry, Ludovic Dey, Beat Müller, Patrick Hunziker, Philipp Schütz, Marco Cattaneo, Marc Y. Donath   +25 more
doaj   +1 more source

Canakinumab [PDF]

mAbs, 2010
Canakinumab (ACZ885, Ilaris) is a human anti-IL-1beta monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of IL-1beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of
openaire   +2 more sources

Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events

CJC Open, 2022
Background: Cardiovascular (CV) disease is a condition with high levels of morbidity and mortality. Canakinumab is a novel monoclonal antibody therapy that has been shown to reduce CV events but is associated with side effects and high cost.
Kevin E. Boczar, MD, Rob Beanlands, MD, George Wells, PhD, Doug Coyle, PhD   +3 more
doaj   +1 more source

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia

Immunity, Inflammation and Disease, 2021
Background Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to
Katia Falasca, Myriam Di Penta, Claudio Ucciferri, Antonio Auricchio, Marta Di Nicola, Michele Marchioni, Eleonora Celletti, Emanuela Sabatini, Francesco Cipollone, Jacopo Vecchiet   +9 more
doaj   +1 more source

Expedited Desensitization to Canakinumab

Allergy & Rhinology, 2020
Introduction Interleukin-1 (IL-1) antagonists have been successful in the management of monogenic auto-inflammatory diseases, notably classic hereditary fever syndromes, such as Familial Mediterranean Fever (FMF). Anakinra (Kineret®), a human recombinant
Neha Sanan DO, Jason Schend DO, Marija Rowane OMS-III, Robert Hostoffer DO, FAAFP, FACOP   +3 more
doaj   +1 more source

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study

Frontiers in Medicine, 2023
IntroductionThe blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome,
Ekaterina Alexeeva, Ekaterina Alexeeva, Meiri Shingarova, Meiri Shingarova, Tatyana Dvoryakovskaya, Tatyana Dvoryakovskaya, Olga Lomakina, Anna Fetisova, Ksenia Isaeva, Aleksandra Chomakhidze, Kristina Chibisova, Elizaveta Krekhova, Aleksandra Kozodaeva, Kirill Savostyanov, Aleksandr Pushkov, Ilya Zhanin, Dmitry Demyanov, Evgeny Suspitsin, Evgeny Suspitsin, Konstantin Belozerov, Mikhail Kostik   +20 more
doaj   +1 more source

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

BMC Musculoskeletal Disorders, 2011
Background Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA).
Arulmani Udayasankar, Preiss Ralph, Krammer Gerhard, Sebba Anthony, Beaulieu Andre, Durez Patrick, Gomez-Reino Juan, Alten Rieke, Widmer Albert, Gitton Xavier, Kellner Herbert   +10 more
doaj   +1 more source

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Pediatric Rheumatology Online Journal, 2019
Background Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease, caused by gain of function mutation in NLRP3 resulting in excess production of interleukin-1 (IL-1).
Abdulkadir A. Elmi, Karen Wynne, Iek L. Cheng, Despina Eleftheriou, Helen J. Lachmann, Philip N. Hawkins, Paul Brogan   +6 more
doaj   +1 more source